Pharma

Your Article Summary

See Latest Articles

Sirion Therapeutics Merges With Sytera to Develop New Treatments For Eye Disease
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/17/06

Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceutical company, announced that it has completed a merger with Sytera, Inc., a biopharmaceutical firm based in La Jolla, California committed to discovering new treatments for dry AMD (age- related macular degeneration). The announcement was made jointly by Sirion President and CEO Barry Butler, and Sytera Chairman and CEO Kenneth J. Widder, M.D. The financial terms were not disclosed

Today in M&A/Partnerships...keeping you current

Receive free subspecialty "5-minute updates" via email

New graduate degree offered focusing on health care quality
National Committee for Quality Assurance (NCQA), 06/11/09

GSK Signs Deal with Concert Pharma to the Tune of $1 Billion
PharmExec, 06/04/09

Sanofi-aventis and Kyowa Hakko Kirin enter into a Collaboration and Licensing Agreement on an Anti LIGHT fully human monoclonal antibody
Sanofi-aventis, 05/15/09

See All of M&A/Partnerships

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Erlotinib Warning
JAMA, 06/29/09

Astellas Names Head of Global R and D Operations
Astellas, 06/11/09

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
Expert Opinion in Pharmacotherapy, 06/19/09

See All of Research & Development